Parkinson's Disease HIF/Hypoxia Signaling Therapy Companies

Overview

Hypoxia-inducible factor (HIF) signaling represents a promising neuroprotective approach for Parkinson's disease. Companies are developing prolyl hydroxylase inhibitors (PHIs) that stabilize HIF-α subunits, activating protective gene programs including VEGF, erythropoietin (EPO), BNIP3, and glycolytic enzymes. This approach addresses the "pseudo-hypoxic state" created by mitochondrial complex I dysfunction in PD dopaminergic neurons.

This category covers companies developing HIF-targeting therapeutics for PD, including clinically approved PHD inhibitors being repurposed for neurodegeneration and novel brain-penetrant compounds in development.

Key Companies

Akros Pharma — Vadadustat

Mechanism: Oral prolyl hydroxylase inhibitor (PHD1-3)

Clinical Stage: Phase II (AD/PD)

Background: Akros Pharma is advancing vadadustat, an oral PHD inhibitor originally developed for anemia of chronic kidney disease, for CNS applications. The company has initiated Phase II trials in Alzheimer's disease and is exploring Parkinson's disease indications. Preclinical data demonstrate that vadadustat crosses the blood-brain barrier and provides neuroprotection in MPTP and 6-OHDA models of PD[@akros2024].

Key Science:

• PHD inhibition stabilizes HIF-1α and HIF-2α, activating protective gene programs
• HIF target genes include VEGF, EPO, BNIP3, and glycolytic enzymes
• Neuroprotective effects demonstrated in dopaminergic neuron cultures
• Oral administration enables chronic dosing for neurodegenerative diseases

Overview

Hypoxia-inducible factor (HIF) signaling represents a promising neuroprotective approach for Parkinson's disease. Companies are developing prolyl hydroxylase inhibitors (PHIs) that stabilize HIF-α subunits, activating protective gene programs including VEGF, erythropoietin (EPO), BNIP3, and glycolytic enzymes. This approach addresses the "pseudo-hypoxic state" created by mitochondrial complex I dysfunction in PD dopaminergic neurons.

This category covers companies developing HIF-targeting therapeutics for PD, including clinically approved PHD inhibitors being repurposed for neurodegeneration and novel brain-penetrant compounds in development.

Key Companies

Akros Pharma — Vadadustat

Mechanism: Oral prolyl hydroxylase inhibitor (PHD1-3)

Clinical Stage: Phase II (AD/PD)

Background: Akros Pharma is advancing vadadustat, an oral PHD inhibitor originally developed for anemia of chronic kidney disease, for CNS applications. The company has initiated Phase II trials in Alzheimer's disease and is exploring Parkinson's disease indications. Preclinical data demonstrate that vadadustat crosses the blood-brain barrier and provides neuroprotection in MPTP and 6-OHDA models of PD[@akros2024].

Key Science:

• PHD inhibition stabilizes HIF-1α and HIF-2α, activating protective gene programs
• HIF target genes include VEGF, EPO, BNIP3, and glycolytic enzymes
• Neuroprotective effects demonstrated in dopaminergic neuron cultures
• Oral administration enables chronic dosing for neurodegenerative diseases

• Phase II trial in AD (NCT05678014) — cognitive outcomes
• Planning for PD-specific trials focused on motor function preservation
• Biomarker development for HIF activation in CNS

FibroGen / Astellas — Roxadustat

Mechanism: Oral prolyl hydroxylase inhibitor (PHD1-3)

Clinical Stage: Approved for anemia (CKD); preclinical for PD

Background: Roxadustat (FG-4592) is approved in multiple countries for anemia associated with chronic kidney disease. FibroGen and partner Astellas are exploring CNS applications. Roxadustat has demonstrated neuroprotective effects in multiple preclinical PD models, including MPTP-induced dopaminergic toxicity and 6-OHDA lesions[@fibrogen2024].

Key Science:

• First-in-class oral PHD inhibitor with proven safety in CKD patients
• Brain penetration demonstrated in preclinical models
• Activates HIF-dependent neuroprotective pathways
• May address the pseudo-hypoxic state in PD substantia nigra

• Approved for anemia in China, Japan, Europe, and US
• Investigator-initiated preclinical PD studies at academic centers
• Potential for repurposing under existing safety data

Daiichi Sankyo — DS-1090

Mechanism: Brain-penetrant prolyl hydroxylase inhibitor

Clinical Stage: Preclinical (CNS)

Background: Daiichi Sankyo is developing DS-1090, a PHD inhibitor specifically optimized for CNS penetration. The company has modified the roxadustat scaffold to enhance blood-brain barrier crossing. Preclinical studies show superior brain exposure compared to first-generation PHD inhibitors with maintained PHD inhibition potency[@daiichi2024].

Key Science:

• Enhanced BBB penetration through modified physicochemical properties
• Maintains HIF stabilization activity with lower peripheral exposure
• Potential for higher CNS doses without causing polycythemia
• Designed specifically for neurodegenerative indications

• IND-enabling studies ongoing
• Target indication: Alzheimer's and Parkinson's disease
• Expected to enter clinical trials 2025-2026

Avid Bioservices — AKB-6899

Mechanism: HIF-1α direct stabilizer (non-PHD mechanism)

Clinical Stage: Preclinical

Background: Avid Bioservices is developing AKB-6899, a direct HIF-1α stabilizer that bypasses PHD inhibition. This approach may offer more selective HIF-1α activation without affecting PHD enzymes involved in other cellular processes. Preclinical data show neuroprotection in oxidative stress models relevant to PD[@avid2024].

Key Science:

• Direct HIF-1α stabilization (different mechanism from PHD inhibitors)
• Potential for selective HIF-1α vs. HIF-2α activation
• May reduce off-target effects associated with broad PHD inhibition
• Novel chemical scaffold with differentiated pharmacology

• Lead optimization complete
• Preclinical efficacy studies in PD models
• Target: IND filing 2026

Restartis Therapeutics — Novel PHD Inhibitors

Mechanism: Isoform-selective PHD inhibitors

Clinical Stage: Discovery/Preclinical

Background: Restartis Therapeutics is developing next-generation PHD inhibitors with selectivity for specific PHD isoforms (PHD1 vs. PHD2 vs. PHD3). Different isoforms may have distinct roles in neuronal survival, with PHD2 inhibition being particularly relevant for neuroprotection. The company aims to develop compounds with improved therapeutic index[@restartis2024].

Key Science:

• PHD isoform selectivity may improve safety profile
• PHD2 inhibition sufficient for neuroprotection with reduced erythrocytosis
• Novel scaffolds distinct from existing PHD inhibitors
• Focus on ALS and PD indications

• Lead identification ongoing
• Optimization for CNS penetration
• Partnering discussions for clinical development

Cerebral Therapeutics — Brain-Penetrant HIF Stabilizers

Mechanism: AAV-mediated HIF-1α gene therapy

Clinical Stage: Preclinical

Background: Cerebral Therapeutics is developing AAV-delivered HIF-1α constructs for sustained HIF activation in the brain. Unlike small molecule approaches requiring chronic dosing, gene therapy could provide long-term HIF stabilization. The company is targeting PD and other neurodegenerative conditions[@cerebral2024].

Key Science:

• AAV vector with CNS-targeted delivery (intranasal or intracisternal)
• Sustained HIF-1α expression from single administration
• Regulated expression systems to control HIF levels
• Potential for combination with other gene therapies

• Vector optimization complete
• Efficacy studies in PD models
• Target: First-in-human study 2027

Academic/Government Programs

| Institution | Approach | Status |
|-------------|----------|--------|
| NIH/NINDS | PHD inhibitor repurposing program | Preclinical |
| Stanford University | HIF-1α gene therapy | Preclinical |
| University of Pennsylvania | BNIP3-targeted approaches | Research |
| UCL Queen Square | Hypoxic preconditioning protocols | Clinical (repurposed) |

Mechanism of Action

HIF Signaling in PD

Therapeutic Rationale

The HIF pathway is particularly relevant for PD because:

Pipeline Overview

| Company | Compound | Mechanism | Stage | Target Indication |
|---------|----------|-----------|-------|-------------------|
| Akros Pharma | Vadadustat | PHD inhibitor | Phase II | AD/PD |
| FibroGen/Astellas | Roxadustat | PHD inhibitor | Preclinical | PD |
| Daiichi Sankyo | DS-1090 | Brain-penetrant PHDi | Preclinical | AD/PD |
| Avid Bioservices | AKB-6899 | Direct HIF-1α stab. | Preclinical | PD |
| Restartis | Novel PHDi | Isoform-selective | Discovery | ALS/PD |
| Cerebral Therapeutics | AAV-HIF | Gene therapy | Preclinical | PD |

Scientific Rationale

Evidence for HIF in PD

• Post-mortem studies: Elevated HIF-1α and HIF-2α in PD substantia nigra[@va2009]
• Preclinical models: PHD inhibitors reduce dopaminergic neuron loss in MPTP/6-OHDA models
• Clinical observations: Anemia patients on PHD inhibitors show possible neuroprotective signals
• Genetic links: PHD2 (EGLN1) variants associated with PD risk

Challenges and Considerations

| Challenge | Mitigation |
|-----------|------------|
| Chronic vs. acute timing | Precise dosing protocols, biomarkers |
| Polycythemia risk | Brain-penetrant compounds, isoform selectivity |
| Tumor promotion concerns | Limited duration, patient monitoring |
| BBB penetration | Structural modifications, alternate delivery |
| Biomarker development | HIF target gene expression monitoring |

Key Open Questions

Cross-References

• [HIF/Hypoxia Signaling in Parkinson's Disease](/mechanisms/hif-hypoxia-signaling-parkinsons-disease) — mechanism page
• [HIF Therapeutics for Neurodegeneration — Investment Analysis](/investment/hif-therapeutics-neurodegeneration) — investment landscape
• [Parkinson's Disease](/diseases/parkinsons-disease) — disease overview
• [PD Mitochondrial Neuroprotection Companies](/companies/pd-mitochondrial-neuroprotection-companies) — related approach
• [PD VEGF/Angiogenic Signaling Companies](/companies/pd-vegf-angiogenic-signaling-therapy-companies) — related pathway

References